About me


I am Hiroaki Murayama, working on mathematical modelling of infectious disease dynamics, epidemiology, and control. I am also a medical student in School of Medicine, International University of Health and Welfare in Japan.

My e-mail adress: hiromura319[at]gmail.com


Infectious Disease Epidemiology

  • Quantification of transmission dynamics and control
  • Theoretical framework construction
  • Bayesian Inference
  • COVID-19
  • Monkeypox

My research work revolves around mathematical formulation of infectious disease dynamics to contribute to public health issues. For directly transmitted diseases, each of observed cases are not independent (infector-infectee relationship), which is often referred to as dependent happening. This phenomenon leads to the need for the reconstruction of transmission dynamics in terms of mathematical modelling to account for non-i.i.d. setting.
My main interest lies in quantifying natural history, transmission dynamics, and control (i.e.,non-phermaceutical interventions, vaccine strategy, etc.) and constructing a theoretical framework in light of Bayesian inference.

[GitHub] [Research Map] [ORCiD] [Google Scholar]

Brief CV

  • Research Assistant, Graduate School of Social Sciences, Chiba University, Japan, 2021 - (present)
  • Advisor, COVID-19 Intervention Group, Ministry of Health, Labour, and Welfare, Japan, 2020 - (present)
  • Medical Student, Department of Medicine, School of Medicine, International University of Health and Welfare, Japan, 2019 - (present)

  • Publications

    Preprint (†: equal contribution)

  • Endo A, Murayama H, Abbott S, Ratnayake R, Pearson CAB, Edmunds WJ, Fearon E†, Funk S†. Heavy-tailed sexual contact networks and the epidemiology of monkeypox outbreak in non-endemic regions, May 2022. medRxiv. 2022 Jun 1;2022.06.13.22276353.
  • Ko KY, Murayama H, Yamasaki L, Kinoshita R, Suzuki M, Nishiura H. Evaluating the Age-Specific Effectiveness of COVID-19 Vaccines Against Death and the Impact of Healthcare Burden on Age-Specific Case Fatality Risk in Tokyo, Japan. SSRN. 2022 Feb.

  • Other Pages